It's a make-or-break year for these battered companies - BNN Bloomberg

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 78 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 35%
  • Publisher: 50%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

U.S. companies had a lot to overcome in the latter half of 2022 with rising interest rates, more budget-conscious consumers and a sagging stock market. That’s left some of them in very tough spots at the start of the new year.

Carnival Corp. entered 2020 with a full head of steam, having reported record sales and profit the year before. Three years into the pandemic, it’s a different company.The cruise line giant, like other ship operators, shut down for more than a year due to COVID. It sold new shares and borrowed heavily, tripling its long-term debt to US$32 billion over the past three years. Rising interest rates will make that sum even tougher to pay down.

Carnival shares trade as if more trouble lies ahead. The stock is down more than 80 per cent since December 2019 — the worst performer among the three big cruise companies — and recently touched a 30-year bottom. “At the end of the day, we think expectations are low,” said Credit Suisse Securities analyst Benjamin Chaiken.It’s also been a rough year for Beyond Meat Inc.

CEO Ethan Brown maintains that plant-based meat will eventually replace the real thing. Investors are far from convinced; the stock has fallen about 95 per cent from its peak in 2019 and short interest accounts for around 40 per cent of the available shares. It’s unclear how long Brown — or his company — will survive without a meaningful turnaround.That’s when when an interest payment is due on its 2029 bonds.

The company’s largest creditors have agreed to jointly work to get a deal with management to refinance its debt. Carvana bonds have traded below 50 cents on the dollar, indicating a high chance of default.Next year will be crucial for Verve Therapeutics Inc., a biotech company developing a gene-editing treatment for heart disease.

Clinical trials are still moving forward overseas, and Verve plans to share data from them next year. That should give investors a better sense of how well the drug might work and how safe it could be. But even if everything looks good, Verve will still need years yet to prove the drug’s promise — and assure investors there’s enough appetite for it. The company says it has enough cash to last through 2025.

 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 83. in DE

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

U.S. stocks notch 69th record close of the year - BNN BloombergU.S. stocks rose for a fourth day in thin trading as investors evaluated prospects for a year-end rally amid spiking coronavirus cases. Oil gained and the Treasury curve flattened. Are you serious? Using 2021 data for 2022? How convenient is that!🤯 Maybe check to see that you arent posting articles from last year oil will rocket forward in 2023 with SPR release ending, Russian not shipping oil, Saudi cutting production........
Herkunft: BNNBloomberg - 🏆 83. / 50 Weiterlesen »

U.S. stocks notch 69th record close of the year - BNN BloombergU.S. stocks rose for a fourth day in thin trading as investors evaluated prospects for a year-end rally amid spiking coronavirus cases. Oil gained and the Treasury curve flattened. This article is from a year ago. I think your bot is broken.
Herkunft: BNNBloomberg - 🏆 83. / 50 Weiterlesen »